Reply to D. Pouessel et al, J.B. Aragon-Ching, and B.A. Adesunloye.
Fox Chase Cancer Center, Philadelphia, PA elizabeth.plimack@fccc.edu.
Elizabeth R
ER
Plimack
Thomas Jefferson University Hospital, Philadelphia, PA.
Jean
J
Hoffman-Censits
Memorial Sloan Kettering Cancer Center, New York, NY.
Jonathan E
JE
Rosenberg
Fox Chase Cancer Center, Philadelphia, PA.
Yu-Ning
YN
Wong
Dana-Farber Cancer Institute, Boston, MA.
Joaquim
J
Bellmunt
Dana-Farber Cancer Institute, Boston, MA.
Toni K
TK
Choueiri
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000032:analysis*; D002295:Carcinoma, Transitional Cell / Q000737:chemistry* / Q000188:drug therapy*; D015653:Cystectomy; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D020360:Neoadjuvant Therapy / Q000379:methods*; D020011:Protective Agents / Q000627:therapeutic use*; D001749:Urinary Bladder Neoplasms / Q000737:chemistry* / Q000188:drug therapy*
D014408:Biomarkers, Tumor; D020011:Protective Agents; D016179:Granulocyte Colony-Stimulating Factor